Time-release versus immediate-release formulations of venlafaxine, paroxetine and bupropion: a comparative study of a nationally representative sample of the US working population
Abstract
Objective The purpose of this study is to compare patient-reported outcomes (PROs) such
as health-related quality of life, mental disorder and psychological distress among users of
time-release (TR) versus immediate-release formulations of three commonly prescribed
antidepressants in a sample of the US working population.
Methods Adjusted multiple linear and logistic regression analyses using data from 2004 to
2010 Medical Expenditures Panel Surveys were conducted. The health-related quality of life
was measured based on the Physical Component Summary (PCS-12) and the Mental
Component Summary (MCS-12) of the SF-12v2. The mental disorder and the psychological
distress were measured by the Patient Health Questionniare-2 and the Kessler 6 respectively.
Key findings The utilization of TR formulations was not associated with higher scores in
the SF12-v2, (β = −0.546, P = 0.442) and (β = −0.806, P = 0.346) for both PCS-12 and
MCS-12 respectively. The users of TR formulations did not significantly differ in their
likelihood of having a score of ≥3 in the Patient Health Questionniare-2 (OR = 1.048,
P = 0.677). Furthermore, the utilization of TR formulations was not associated with lower
scores in the Kessler 6 Scale (β = 0.073, P = 0.846).
Conclusions Although controlled clinical trials report favourable tolerability profiles for
TR formulations, it still remains unclear whether these formulations lead to better PROs in
real-world patient-care settings.
Keywords health-related quality of life; immediate-release; mental component summary
score of SF-12v2; Patient Health Questionnaire-2; physical component summary score of
SF-12v2; time-release
